242 related articles for article (PubMed ID: 3937059)
21. Deprenyl (selegiline): the history of its development and pharmacological action.
Knoll J
Acta Neurol Scand Suppl; 1983; 95():57-80. PubMed ID: 6428148
[TBL] [Abstract][Full Text] [Related]
22. The effect of various monoamine oxidase (MAO) inhibitors on the response of blood pressure of rats and cats to tyramine.
Abdo-Rubo A
Acta Physiol Hung; 1990; 75(4):321-36. PubMed ID: 2127505
[TBL] [Abstract][Full Text] [Related]
23. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
24. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.
Worms P; Kan JP; Wermuth CG; Roncucci R; Bizière K
J Pharmacol Exp Ther; 1987 Jan; 240(1):241-50. PubMed ID: 3100770
[TBL] [Abstract][Full Text] [Related]
25. Selective pressor enhancement by monoamine oxidase inhibitors in conscious rats.
Kerecsen L; Bunag RD
J Pharmacol Exp Ther; 1989 Nov; 251(2):645-9. PubMed ID: 2509682
[TBL] [Abstract][Full Text] [Related]
26. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
27. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
[TBL] [Abstract][Full Text] [Related]
28. Comparative ex vivo inhibitory effects of (E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine (MDL 72145) on amine oxidase activities in the rat.
Lyles GA; Marshall CM; Flucker CJ
Biochem Pharmacol; 1989 Sep; 38(17):2937-40. PubMed ID: 2775316
[No Abstract] [Full Text] [Related]
29. Cardiovascular changes in response to selective monoamine oxidase inhibition in the rat.
Cohen RM; Campbell IC; Yamaguchi I; Pickar D; Kopin IJ; Murphy DL
Eur J Pharmacol; 1982 May; 80(1):155-60. PubMed ID: 6284529
[TBL] [Abstract][Full Text] [Related]
30. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
Riederer P; Youdim MB
J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
[TBL] [Abstract][Full Text] [Related]
32. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake.
Fang J; Yu PH
Neuropharmacology; 1994 Jun; 33(6):763-8. PubMed ID: 7936114
[TBL] [Abstract][Full Text] [Related]
33. The pharmacology of (-)deprenyl.
Knoll J
J Neural Transm Suppl; 1986; 22():75-89. PubMed ID: 3097262
[TBL] [Abstract][Full Text] [Related]
34. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Fuller RW; Hemrick-Luecke SK; Perry KW
J Pharmacol Exp Ther; 1988 Nov; 247(2):531-5. PubMed ID: 3141609
[TBL] [Abstract][Full Text] [Related]
35. [Cardiovascular effects of (+)- and (-)-tranylcypromine compared to other monoamine oxidase inhibitors in animal studies (author's transl)].
Dénes B; Greeff K; Tawfik H
Arzneimittelforschung; 1982; 32(3):201-7. PubMed ID: 6805481
[TBL] [Abstract][Full Text] [Related]
36. Lesion-induced reductions in trace amine accumulation: dependence on MAO inhibitor pretreatment.
Nguyen TV; Juorio AV; Greenshaw AJ
Brain Res Bull; 1989 Feb; 22(2):197-200. PubMed ID: 2495844
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic aspects of deprenyl effects.
Magyar K; Tóthfalusi L
Pol J Pharmacol Pharm; 1984; 36(4):373-84. PubMed ID: 6441926
[TBL] [Abstract][Full Text] [Related]
38. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
Bondiolotti GP; Galva MD; Villa F; Sciaba L; Picotti GB
Biochem Pharmacol; 1995 Jun; 50(1):97-102. PubMed ID: 7605351
[TBL] [Abstract][Full Text] [Related]
39. Tyramine pressor sensitivity changes during deprenyl treatment.
Sunderland T; Mueller EA; Cohen RM; Jimerson DC; Pickar D; Murphy DL
Psychopharmacology (Berl); 1985; 86(4):432-7. PubMed ID: 3929314
[TBL] [Abstract][Full Text] [Related]
40. Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships.
McDonald IA; Lacoste JM; Bey P; Palfreyman MG; Zreika M
J Med Chem; 1985 Feb; 28(2):186-93. PubMed ID: 3968682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
